The Series B Preferred authorization is the dominant risk factor — monitor for any conversion notices or further issuances that would massively dilute common shareholders. The biotech asset sale via Farrington is the only potential catalyst for meaningful cash, but the LOI is non-binding and success-based. The crypto pivot narrative is speculative and unlikely to generate near-term cash. Given the extreme dilution overhang, shorts may accumulate; avoid long positions until the company demonstrates a credible path to non-dilutive funding or a definitive asset sale.
Price Chart
Executive Summary
Bio-Path Holdings is executing a radical pivot from a cash-strapped biotech to a crypto-focused digital asset treasury company, creating massive potential dilution by authorizing 5 million Series B Preferred shares (each convertible into 1,000 common shares) and using them to acquire crypto assets, pay executives, and issue shares to partnerships. The company has only raised ~$28,000 in net proceeds from recent Regulation A sales, owes over $355,000 to MD Anderson to restart Phase 2 trials, and has signed non-binding LOIs to sell its biotech IP and partner with altFINS for crypto treasury management. The extreme dilution potential, combined with the company's lack of operating revenue and reliance on speculative crypto narratives, presents a highly bearish outlook.
Key Facts
- Authorized 5,000,000 Series B Preferred shares, each convertible into 1,000 common shares, creating potential for 5 billion common shares of dilution.
- Raised only $13,983 and $14,676 from Regulation A common stock sales in April/May 2026, leaving $571,341 remaining capacity.
- Owes MD Anderson $292,264.21 for BP1001-201-AML and $63,286.55 for BP1002-201-AML to restart Phase 2 trials.
- Issued 22,342 Series B Preferred shares (subscription payable) to acquire Himalaya Technologies (HMLA) shares valued at $670,260, making HMLA a majority-owned subsidiary.
- Issued 369 Series B Preferred shares to CEO Vikram Grover for a software platform valued at $11,069.
- Himalaya Technologies canceled 9,684,43 Series B Preferred shares, representing half of the company's diluted shares outstanding.
- Signed LOI with altFINS to issue 2,500,000 common share equivalents (CSEs) in exchange for an option to buy up to 22% of altFINS for €2 million.
- Added Richard Fetyko (altFINS CEO) to advisory board with 100,000 common stock purchase warrants at $0.03 per share.
- Engaged Farrington Capital Group to find a buyer or licensor for all biotech assets (DNAbilize platform, BP1001, BP1002, BP1003) with 60-day exclusivity and success-based fees.
- Opened a Coinbase account to manage a digital asset treasury, intending to allocate up to 50% of capital raised to crypto.
Financial Impact
Extreme dilution from Series B Preferred: each of the 5,000,000 authorized shares converts into 1,000 common shares, potentially adding 5 billion common shares to the current float. The company has negligible cash ($571k remaining Reg A capacity) and $355k in outstanding liabilities to MD Anderson.
Risk Factors
- Massive dilution from Series B Preferred conversion — each share converts to 1,000 common shares, with 5 million authorized.
- Inability to pay MD Anderson back-arrears ($355k) to restart Phase 2 trials — biotech pipeline effectively stalled.
- Crypto treasury strategy is speculative and unproven; allocation of up to 50% of capital to volatile crypto assets introduces additional risk.
- Non-binding LOIs with Farrington and altFINS may not result in definitive agreements — no cash or binding commitments yet.
- Majority-owned subsidiary HMLA (Himalaya Technologies) is an early-stage crypto social platform with no revenue disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (BPTH) — Batch item 1 | 0001663577-26-000218 |
| Exhibit: ex10_1.htm | 0001663577-26-000218 |
| Document: bpth_8k071626.htm | 0001663577-26-000218 |
| Document: 0001663577-26-000218-index-headers.html | 0001663577-26-000218 |
| Document: 0001663577-26-000218-index.html | 0001663577-26-000218 |
| Document: 0001663577-26-000218.txt | 0001663577-26-000218 |
| 8-K Filing (BPTH) — Batch item 7 | 0001663577-26-000218 |
| Exhibit: ex10_1.htm | 0001663577-26-000218 |
| Document: bpth_8k071626.htm | 0001663577-26-000218 |
| Document: 0001663577-26-000218-index-headers.html | 0001663577-26-000218 |
| Document: 0001663577-26-000218-index.html | 0001663577-26-000218 |
| Document: 0001663577-26-000218.txt | 0001663577-26-000218 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 16, 2026 14w ago | 8-K | $0.0400 $0.000200 | ▲ +99.50% | ▲ +103.47% | $0.000300 (+99.25%) |
May 26, 2026 21w ago | 8-K | $0.0400 $0.0339 | ▲ +15.25% | ▲ +17.97% | $0.000300 (+99.25%) |
Feb 24, 2026 34w ago | 8-K | $0.0700 $0.0200 | ▼ −71.43% | ▼ −78.18% | $0.000300 (−99.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers